Sun L, Brentnall A, Patel S, et al. - Through this cost-efficient microsimulation modeling study including data from 11,836 women, researchers predicted incremental lifetime impacts, costs, and cost-efficiency of multigene testing of all individuals with breast cancer (BC) in contrast with the current practice of genetic testing (BRCA) on the basis of family history (FH) or clinical criteria. Every woman with BC underwent BRCA1/BRCA2/PALB2 testing. For all individuals with BC to be remarkably cost-effective, unselected, high-risk multigene testing was discovered, in comparison with testing on the basis of FH or clinical criteria for UK and US health systems. This verdict supports altering the prevailing policy to extend genetic testing to every woman with BC.